| Breast Cancer |
1 |
1 |
| Ovarian Cancer |
0 |
0.81 |
| Triple Negative Breast Cancer |
0 |
0.99 |
| BRCA |
0 |
0.46 |
| Chemotherapy |
0 |
0.46 |
| Breast |
0 |
0.42 |
| Cancer |
0 |
0.38 |
| Neoadjuvant Therapy |
0 |
0.34 |
| Toxicology |
0 |
0.34 |
| Surgery |
0 |
0.17 |
| Grant |
0 |
0.13 |
| Platinum |
0 |
0.13 |
| Clinical Guidelines |
0 |
0.08 |
| Myelodysplastic Syndrome |
0 |
0.07 |
| Acute Leukemia |
0 |
0.06 |
| Acute Myeloblastic Leukemia |
0 |
0.06 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.06 |
| Adjuvant Therapy |
0 |
0.04 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.04 |
| Europe |
0 |
0.04 |
| HIV Infection |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.04 |
| Travel Medicine |
0 |
0.04 |